In a recent work the comparison between three different AD mice model, APP (Tg2576), Tau/Tau (JNPL3) and APP/Tau (Tg2576/ JNPL3), after Deferasirox administration showed that although the treatment did not affect memory and motor functions, but it revealed a reduction in tau hyperphosphorylation. This evidence concerns the gene MAPT and Alzheimer disease.